Jeffrey L. Dage, PhD, is a Senior Research Professor of Neurology and Primary Member, Stark Neurosciences Research Institute at Indiana University School of Medicine. He holds a secondary appointment in the Department of Medical and Molecular Genetics. The current focus of his research is the discovery and development of biomarkers to aid in the understanding of neurodegenerative diseases.
Prior to joining IU, Dr. Dage was a Research Fellow at Eli Lilly and Company. He has over 20 years of experience in drug discovery and early clinical development holding roles as an individual contributor, scientific group leader and management. He has successfully led research groups in diverse areas such as analytical chemistry, stem cell biology and translational science with broad impact across therapeutic areas.
Dr. Dage has continually been on the forefront of identification, development, and application of novel technologies that answer disease relevant biological questions encountered in the course of drug discovery and clinical development. Most recently he has led the discovery and development of phosphorylated tau as a novel blood biomarker for Alzheimer’s disease clinical trials.
This breakthrough led to several news articles in 2020 that are included under the “Media Tab” as additional context on Dr. Dage’s discovery. This blood test has proven to be useful for identification of Alzheimer’s disease pathology and risk of cognitive decline.
You can find Dr. Dage's Lab page here.